6,382 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by EntryPoint Capital LLC

EntryPoint Capital LLC acquired a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,382 shares of the company’s stock, valued at approximately $223,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC grew its position in shares of Ionis Pharmaceuticals by 160.0% during the 4th quarter. Signaturefd LLC now owns 949 shares of the company’s stock valued at $33,000 after acquiring an additional 584 shares during the period. Lindbrook Capital LLC increased its position in shares of Ionis Pharmaceuticals by 183.8% in the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock valued at $36,000 after buying an additional 671 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in shares of Ionis Pharmaceuticals by 40.9% in the third quarter. Itau Unibanco Holding S.A. now owns 1,081 shares of the company’s stock valued at $43,000 after buying an additional 314 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $51,000. Finally, Quest Partners LLC lifted its position in shares of Ionis Pharmaceuticals by 94.8% during the 3rd quarter. Quest Partners LLC now owns 2,674 shares of the company’s stock valued at $107,000 after buying an additional 1,301 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $31.15 on Friday. Ionis Pharmaceuticals, Inc. has a 52-week low of $30.23 and a 52-week high of $52.34. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The stock has a market cap of $4.95 billion, a price-to-earnings ratio of -10.25 and a beta of 0.28. The business has a fifty day moving average of $32.53 and a two-hundred day moving average of $35.75.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. Ionis Pharmaceuticals’s revenue was down 30.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.12 EPS. As a group, research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on IONS. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. BMO Capital Markets decreased their price target on shares of Ionis Pharmaceuticals from $60.00 to $45.00 and set a “market perform” rating on the stock in a research note on Thursday, February 20th. Citigroup cut their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, JPMorgan Chase & Co. lowered their price target on Ionis Pharmaceuticals from $47.00 to $45.00 and set a “neutral” rating on the stock in a research note on Monday, March 24th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.44.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 6,165 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the sale, the executive vice president now owns 57,452 shares of the company’s stock, valued at $1,816,632.24. The trade was a 9.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Eric Swayze sold 7,154 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the transaction, the executive vice president now owns 45,670 shares of the company’s stock, valued at approximately $1,499,802.80. This represents a 13.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 111,956 shares of company stock valued at $3,608,439. Company insiders own 2.71% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.